Triple G 8 mg (Retatrutide) vial

Retatrutide (reagent vial) - characteristics

Retatrutide is an advanced research peptide, belonging to the incretin analogue group, analysed in the context of the regulation of metabolic pathways related to energy metabolism and glucose homeostasis. Its activity focuses on receptors involved in the control of metabolic signalling, including processes related to energy balance, insulinotropic response and regulation of energy intake. Due to its complex receptor profile, retatrutide is an important research target in the fields of modern biochemistry, endocrinology and molecular pharmacology. The product, in reagent form in a vial, is intended exclusively for laboratory use and scientific analysis. More information on the characterisation of the compound is available in the scientific literature and in section research.

Retatrutide - how does it work?

Retatrutide is a compound being investigated for its effects on metabolic processes. Its mechanism of action is based on the simultaneous activation of GLP-1, GIP and glucagon receptors (GCGR), which distinguishes it from compounds that only act on a single receptor pathway. The available scientific literature indicates that activity towards GLP-1 and GIP receptors may be associated with modulation of satiety sensation and the body's metabolic response. Effects on gastric emptying have also been described, which studies have analysed in the context of controlling energy intake. At the same time, effects on pathways related to carbohydrate metabolism have been linked to glucose-dependent modulation of insulin secretion and effects on glucagon secretion. In contrast, activation of the GCGR receptor remains a focus of research in the areas of energy expenditure, lipid metabolism and energy balance, which distinguishes retatrutide from classical agonists GLP-1 i GLP-1/GIP

Retatrutide versus other investigational peptides - study information

In research at McGill University in Montreal, researchers analysed three commercially available GLP-1 analogues and nine formulations still awaiting marketing approval. Their study found that in overweight or obese adults without diagnosed diabetes, the highest weight loss (both in percentage and in kilograms) was observed after weekly use of the peptide retatrutide, a triple agonist of GIP, GLP-1 and glucagon receptors.

Source:

The product is intended for scientific research and laboratory analysis. All articles and information on this website are for informational and educational purposes only.